AD-MSCs are considered an acceptable alternative for BM-MSCs because of their advantages, including ease of isolation via liposuction with minimal discomfort to patients, more abundance, potentially higher stemness, and more in vitro proliferation and expansion capacity without entering senescence, producing a higher amount of bioactive mediators such as hepatocyte growth factor (HGF) and cytokine (IL-1, IL-6, IL-8) receptor antagonists [96–98]. The gene discussed is IL1B; the disease is Alzheimer disease.